Investigational Blood Test Detects Early-Stage Pancreatic Cancer

New Blood Test Combines Three Biomarkers for Early Detection

An international trial published in Nature Medicine reported that an investigational blood test called PANXEON detected early-stage pancreatic cancer in 87 percent of cases. Researchers evaluated the liquid biopsy across nearly 1,800 patients in the United States, Europe, and Asia.

The test analyzes three distinct signals from a single blood draw: circulating microRNAs, exosomal microRNAs, and a protein called carbohydrate antigen 19-9 (CA19-9). An artificial intelligence (AI) model combines those three measurements into a unified score that estimates individual risk.

Trial Results Show High Sensitivity in Stages 1 and 2

PANXEON correctly identified stage 1 and stage 2 pancreatic cancers 87 percent of the time in the study cohort. The false-positive rate reached 3 percent among low-risk participants and 16 percent among high-risk groups.

The test also detected high-grade dysplasia in more than 64 percent of cases. That precancerous condition, sometimes classified as stage 0 disease, gives clinicians a chance to intervene before invasive tumors develop.

Targeted Screening for Patients with Elevated Pancreatic Risk

Pancreatic cancer currently carries a five-year survival rate of 14 percent, primarily because 90 percent of diagnoses occur after the tumor spreads. Standard imaging protocols remain costly and invasive, which limits routine surveillance.

Investigators designed the assay to screen people with known risk factors rather than the general public. Those groups include individuals with chronic pancreatitis, pancreatic cysts, or an inherited familial risk.

Clinicians would use abnormal blood scores to guide targeted imaging rather than replacing scans outright.

Study Limitations and Investigational Status

PANXEON remains an experimental test and does not have regulatory approval for commercial clinical use. The 16 percent false-positive rate observed in high-risk patients requires secondary confirmation via imaging to avoid unneeded surgical procedures.

Further prospective studies must confirm whether early surgical interventions guided by this liquid biopsy improve long-term survival rates. Patients with concerns about familial risk or persistent pancreatic symptoms should speak directly with their physician about existing diagnostic options.